PPARA and metabolic dysfunction-associated steatotic liver disease: Elafibranor, combining PPAR- and PPAR- agonism, has shown interesting properties in different rodent models of NAFLD and NASH, decreasing liver fatty acid accumulation and also attenuating pro-inflammatory and pro-fibrotic factors activity [162].